Taken together, the results of our study showed that local administration of low-dose CpG-Stat3 siRNA can enhance the therapeutic potential of IBC in B cell lymphoma and melanoma mouse tumor models, supporting further testing and development of CpG-Stat3 siRNA and ICB combinatory treatment for clinical application. Here, STAT3 is linked to B-cell non-Hodgkin lymphoma.